Drug Discovery

JW Therapeutics acquires Syracuse and license to Eureka’s solid tumour technology in China

JW Therapeutics announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries.

GSK to acquire 10% stake in German biotech company CureVac

British drugmaker GlaxoSmithKline (GSK) has agreed to invest up to €150m to acquire a 10% stake in German biotech company CureVac.

Tonix announces collaboration to develop precision medicine techniques for Covid-19 vaccines and therapeutics

Tonix Pharmaceuticals Holding, a clinical-stage biopharmaceutical company, announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

Novartis to offer not-for-profit medicines to treat Covid-19 patients

Swiss pharmaceutical firm Novartis has announced that its Sandoz division will provide a portfolio of 15 not-for-profit generic and over-the-counter (OTC) medicines to developing countries to treat the patients with Covid-19 symptoms.

US university says common FDA-approved drug may effectively neutralise SARS-CoV-2 virus

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.

Roche, Blueprint Medicines sign $1.7bn worth deal for pralsetinib

Roche and Blueprint Medicines have signed a global licensing and collaboration deal worth up to $1.7bn for the latter's pralsetinib, an investigational treatment for RET-altered cancers.

Merck opens largest M Lab Collaboration Centre in Shanghai

Merck, a leading science and technology company, opened its M Lab Collaboration Centre in Shanghai, the company's largest of nine centers worldwide.

Kymera Therapeutics, Sanofi collaborate to advance novel protein degrader therapies to patients

Kymera Therapeutics announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialise first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.

Pfizer commits $100m to support development of new antibiotics

Major drugmaker Pfizer has committed $100m to the new Antimicrobial Resistance (AMR) Action Fund, which will support the development of new antibiotics due to increasing antibiotic-resistant infections.